Dr. Reddy’s completes clinical studies of its rituximab biosimilar for filing in the U.S., Europe
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions